Soligenix Showcases Platform-Based Drug Development Strategy for Multiple Dermatologic Indications

Soligenix Inc. (NASDAQ: SNGX) was featured in a recent article discussing its positioning in a landscape where modern biopharmaceutical innovation often revolves around a powerful idea: one scientific mechanism can unlock treatments for multiple diseases. The publication noted that Soligenix exemplifies this strategy through its use of synthetic hypericin across two distinct dermatologic indications, illustrating how platform science can streamline development and expand clinical impact. Platform-based drug development has gained traction across the biotechnology industry because of its efficiency and risk management advantages.

In drug development, platform technology is a foundational technology or system that serves as a base for the development of multiple products, solutions or applications, particularly in the life sciences, pharmaceutical and biotech industries. By leveraging a shared mechanism of action, manufacturing process or delivery system, companies can reduce redundancy in preclinical work, regulatory documentation and safety validation. Soligenix's Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (SGX301 or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).

With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, the company's first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and SGX945 in Behçet's disease. The company's approach demonstrates how a single platform can address multiple unmet medical needs while optimizing development resources.

The company's Public Health Solutions business segment includes development programs for RiVax®, its ricin toxin vaccine candidate, as well as its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax™, the company's vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of Soligenix's vaccine programs incorporates the use of its proprietary heat stabilization platform technology, known as ThermoVax®. To date, this business segment has been supported with government grants and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA).

For further information, visit the company's website at https://www.Soligenix.com. The latest news and updates relating to SNGX are available in the company's newsroom at https://ibn.fm/SNGX. This platform-based approach represents a strategic shift in biopharmaceutical development that could potentially accelerate treatments for rare diseases while managing development risks more effectively than traditional single-indication approaches.